Currently out of the existing stock ratings of Stephen Willey, 268 are a BUY (74.65%), 91 are a HOLD (25.35%).

Stephen Willey

Work Performance Price Targets & Ratings Chart

Analyst Stephen Willey, currently employed at STIFEL, carries an average stock price target met ratio of 48.6% that have a potential upside of 39.01% achieved within 212 days.

Stephen Willey’s has documented 682 price targets and ratings displayed on 65 stocks. The coverage is on Healthcare, Consumer Defensive, Technology, Basic Materials sectors.

Most recent stock forecast was given on NKTX, Nkarta at 14-Aug-2026.

Wall Street Analyst Stephen Willey

Analyst best performing recommendations are on INO (INOVIO PHARMACEUTICALS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 5/6/2020. The price target of $21 was fulfilled within 1 day with a profit of $4.15 (16.5%) receiving and performance score of 165.01.

Average potential price target upside

of $295.48 (93.81%) on CUE (CUE BIOPHARMA).
of $92.83 (76.72%) on LUMO (LUMOS PHARMA).
of $84.1 (83.03%) on VOR (VOR BIOPHARMA).

ADGI Adagio Therapeutics AKAO Achaogen AVEO AVEO Pharmaceuticals CNAT Conatus Pharmaceuticals DRNA Dicerna Pharmaceuticals EXEL Exelixis GNCA Genocea Biosciences IGMS IGM Biosciences INCY yte INO Inovio Pharmaceuticals ITMN InterMune LXRX Lexicon Pharmaceuticals MGNX MacroGenics MTEM Molecular Templates NKTX Nkarta NLNK NewLink Genetics NRIX Nurix Therapeutics ONCE Spark Therapeutics RLYP Relypsa SBTX Silverback Therapeutics SGEN Seagen SQZ Sqz Biotechnologies Co ZYME Zymeworks Common Stock AKCA Akcea Therapeutics ALXN Alexion Pharmaceuticals CGEN Compugen GLYC GlycoMimetics MEIP MEI Pharma BCEL Atreca BMRN Biomarin Pharmaceutical LUMO Lumos Pharma BOLT Bolt Biotherapeutics HSTO Histogen IMGO Imago Biosciences TTPH Tetraphase Pharmaceuticals INSM Insmed ALNY Alnylam Pharmaceuticals CMPX Compass Therapeutics CUE Cue Biopharma GERN Geron ISEE IVERIC bio PRTO Proteon Therapeutics VOR Vor Biopharma XFOR X4 Pharmaceuticals IONS Ionis Pharmaceuticals XENE Xenon Pharmaceuticals HLVX Hillevax SPRO Spero Therapeutics TARA Protara Therapeutics ABEO Abeona Therapeutics CBIO Catalyst Biosciences CELC Celcuity LLC CELH Celsius Holdings JANX Janux Therapeutics ACLX Arcellx ARRY Array Technologies BCAX Bicara Therapeutics Common Stock BCE BCE IRON Disc Medicine MT ArcelorMittal SA ADR OABI OmniAb SB Safe Bulkers SG Sweetgreen ABCL Abcellera Biologics AGTC Applied Genetic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Harrison (MORGAN STANLEY)

Sell Since 07-Jan-2022

$-0.48 (-13.79%)

4 years 4 months 15 days ago
(17-May-2022)

2/2 (100%)

$-0.06 (-1.96%)

Please subscribe to see extended stock data

Stephen Willey (STIFEL)

Hold Since 13-May-2022

$1.52 (43.68%)

4 years 4 months 19 days ago
(13-May-2022)

0/2 (0%)

$2.28 (83.82%)

Please subscribe to see extended stock data

Michael Yee (UBS)

Hold Since 23-Dec-2021

$10

$6.52 (187.36%)

4 years 9 months 4 days ago
(28-Dec-2021)

2/3 (66.67%)

$2.15 (27.39%)

Please subscribe to see extended stock data

Seamus Fernandez (GUGGENHEIM)

Hold Since 16-Dec-2021

$40

4 years 9 months 16 days ago
(16-Dec-2021)

1/1 (100%)

$6.16 (18.20%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Stephen Willey most bullish on?

Potential upside of $70.48 has been obtained for CELC (CELCUITY LLC)

Which stock is Stephen Willey most reserved on?

Potential downside of -$7.16 has been obtained for EXEL (EXELIXIS)

What Year was the first public recommendation made by Stephen Willey?

On 2009